{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:15:12Z","timestamp":1782494112911,"version":"3.54.5"},"reference-count":14,"publisher":"Siapec Servizi Srl","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-24-19","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T09:13:40Z","timestamp":1574327620000},"page":"92-97","source":"Crossref","is-referenced-by-count":15,"title":["Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy"],"prefix":"10.32074","volume":"111","author":[{"given":"P.","family":"Gaffuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Espeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fulciniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Paone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21774","published-online":{"date-parts":[[2019,9]]},"reference":[{"key":"10.32074\/1591-951X-24-19_ref1","doi-asserted-by":"crossref","unstructured":"Topalian SL, Taube JM, Anders RA, et al.\n          Mechanism-driven biomarkers to guide immune checkpoint blockade in\n          cancer therapy. Nat Rev Cancer 2016;16:275-87.\n          https:\/\/doi.org\/10.1038\/nrc.2016.36.","DOI":"10.1038\/nrc.2016.36"},{"key":"10.32074\/1591-951X-24-19_ref2","doi-asserted-by":"crossref","unstructured":"Haanen JBAG, Carbonnel F, Robert C, et al.\n          Management of toxicies from immunotherapy: ESMO Clinical Practice\n          Guideline for Diagnosis, treatement and follow-up. Ann Oncol\n          2017;28(Suppl. 4):i119-42.\n          https:\/\/doi.org\/10.1093\/annonc\/mdx225.","DOI":"10.1093\/annonc\/mdx225"},{"key":"10.32074\/1591-951X-24-19_ref3","doi-asserted-by":"crossref","unstructured":"Collins M, Michot J.-M, Danlos F.-X, et al.\n          Gastrointestinal immune related adverse events associated with\n          programmed-Death 1 blockage. J Crohns Colitis 2017;11(Suppl.\n          1):S237.","DOI":"10.1093\/ecco-jcc\/jjx002.440"},{"key":"10.32074\/1591-951X-24-19_ref4","doi-asserted-by":"crossref","unstructured":"Gonzalez RS, Salaria SN, Bohannon CD, et\n          al. PD-1 inhibitor gastroenterocolitis: case series and appraisal of\n          immunomodulatory gastroenterocolitis. Histopathology 2017;70:558-67.\n          https:\/\/doi.org\/10.1111\/his.13118.","DOI":"10.1111\/his.13118"},{"key":"10.32074\/1591-951X-24-19_ref5","doi-asserted-by":"crossref","unstructured":"Onuki T, Morita E, Sakamoto N, et al.\n          Severe upper gastrointestinal disorders in pembrolizumab treated\n          non-small cell lung cancer patient. Respirol Case Rep 2018;6:e00334.\n          https:\/\/doi.org\/10.1002\/rcr2.334.","DOI":"10.1002\/rcr2.334"},{"key":"10.32074\/1591-951X-24-19_ref6","doi-asserted-by":"crossref","unstructured":"Yip RHL, Lee HL, Schaeffer DF, et al.\n          Lymphocitic gastritis induced by pembrolizumab in a patient with\n          metastatic melanoma. Melanoma Research 2018;28:645-7. https:\/\/doi:\n          10.1097\/CMR.0000000000000502.","DOI":"10.1097\/CMR.0000000000000502"},{"key":"10.32074\/1591-951X-24-19_ref7","doi-asserted-by":"crossref","unstructured":"Rao B.B, Robertson S, Philpott J.\n          Checkpoint inhibitor-induced hemorragic gastritis with\n          Pembrolizumab. Am J Gastroenterol 2019;114:196.\n          https:\/\/doi.org\/10.1038\/s41395-018-0366-3.","DOI":"10.1038\/s41395-018-0366-3"},{"key":"10.32074\/1591-951X-24-19_ref8","doi-asserted-by":"crossref","unstructured":"Nishimura Y, Yasuda M, Ocho K, et al.\n          Severe gastritis after administration of nivolumab and ipilimumab.\n          Case Rep Oncol 2018;11:549-56.\n          https:\/\/doi.org\/10.1159\/000491862.","DOI":"10.1159\/000491862"},{"key":"10.32074\/1591-951X-24-19_ref9","doi-asserted-by":"crossref","unstructured":"Kabayashi M, Yamaguchi O, Nagata K, et al.\n          Acute hemorrhagic gastritis after nivolumab treatment. Gastrointest\n          Endosc 2017;86:915-6.\n          https:\/\/doi.org\/10.1016\/j.gie.2017.04.033.","DOI":"10.1016\/j.gie.2017.04.033"},{"key":"10.32074\/1591-951X-24-19_ref10","doi-asserted-by":"crossref","unstructured":"Boike J, Dejulio T. Severe esophagitis and\n          gastritis from nivolumab therapy. ACG case Rep J 2017;4e57.\n          https:\/\/doi.org\/10.14309\/crj.2017.57.","DOI":"10.14309\/crj.2017.57"},{"key":"10.32074\/1591-951X-24-19_ref11","doi-asserted-by":"crossref","unstructured":"Lu J, Firpi-Morell RJ, Dang LH, et al. An\n          unusual case of gastritis in one patient receiving pd-1 blocking\n          therapy: coexisting immune-related gastritis and cytomegaloviral\n          infection. Gastroenterol Res 2018;11:383-7.\n          https:\/\/doi.org\/10.14740\/gr1068w.","DOI":"10.14740\/gr1068w"},{"key":"10.32074\/1591-951X-24-19_ref12","doi-asserted-by":"crossref","unstructured":"Carmack SW, Lash RH, Gulizia JM, et al.\n          Lymphocytic disordes of the gastrointestinal tract: a review for the\n          practicing pathologist. Adv Anat Pathol 2009;16:290-306.\n          https:\/\/doi.org\/10.1097\/PAP.0b013e3181b5073a.","DOI":"10.1097\/PAP.0b013e3181b5073a"},{"key":"10.32074\/1591-951X-24-19_ref13","doi-asserted-by":"crossref","unstructured":"Passat T, Touchefeu Y, Gervois N, et al.\n          Physiopathological mechanisms of immune-related adverse events\n          induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in\n          cancer treatment. Bulletin du Cancer 2018;105:1033-41.\n          https:\/\/doi.org\/10.1016\/j.bulcan.2018.07.005.","DOI":"10.1016\/j.bulcan.2018.07.005"},{"key":"10.32074\/1591-951X-24-19_ref14","doi-asserted-by":"crossref","unstructured":"Day D, Hansen AR. Immune-related adverse\n          events associated with immune checkpoint inhibitors. Bio Drugs\n          2016;30:571-84.\n          https:\/\/doi.org\/10.1007\/s40259-016-0204-3.","DOI":"10.1007\/s40259-016-0204-3"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"http:\/\/www.pathologica.it\/article\/view\/59","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:25:35Z","timestamp":1730813135000},"score":1,"resource":{"primary":{"URL":"https:\/\/old.pathologica.it\/article\/view\/59"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,9]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-24-19","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]},"article-number":"2"}}